Bryan Hambley

Bryan Christopher Hambley , MD,MPH

Assistant Professor of Clinical

Vontz Center

COM IM Hematology/Oncology Division - 0562

Professional Summary

I specialize in the care of patients with blood cancers and have particular expertise in the treatment of patients with leukemia, MDS, and rare hematologic disorders (such as aplastic anemia, other bone marrow failure conditions, and HLH). Within these diseases, I am interested in the role of autologous and allogeneic stem cell transplantation, as well as cellular therapies such as CAR T-cells.


Bachelor's Degree: University of Notre Dame South Bend, IN, 2007 (Pre-Professional Studies and Political Science)

Master's Degree: Tulane University School of Public Health New Orleans, LA, 2012 (Medicine and Health Systems Mangement)

Medical Degree: Tulane University School of Medicine Tulane LA , 2012

Internship: Case Western Reserve University Cleveland, OH, 2015 (Internal Medicine)

Chief Resident: Case Western Reserve University Cleveland, OH, 2016

Fellowship: Case Western Reserve University Cleveland, OH, 2017 (Critical Care)

Fellowship: Johns Hopkins Hospital Baltimore, MD, 2019 (Hematology)

Fellowship: Johns Hopkins Hospital Baltimore, MD, 2020 (Hematology)


American Board of Internal Medicine (Critical Care Medicine) (Certification Date: 12-15-2020 )

American Board of Internal Medicine (Hematology) (Certification Date: 10-25-2019 )

American Board of Internal Medicine (Certification Date: 08-11-2015 )

Clinical Interests

Critical Care Medicine

Hematology and Oncology


Acute Lymphocytic Leukemia

Acute Myeloid Leukemia


Castleman Disease

Chronic Lymphocytic Leukemia

Chronic Myelogenous Leukemia



M Protein


Mediastinal Adenopathy

Monoclonal gammopathy

Monoclonal protein


Mycosis Fugoides

Myelodysplastic Syndrome


Myeloproliferative Disorder


Plasma Cell Disorder

Plasminogen Activator Inhibitor 1

Polycythemia vera


Sideroblastic anemia

T-cell lymphoma


Critical Care Medicine


Internal Medicine

Research Support

Grant: #Cellphire/BARDA TCP CTA Investigators:Cancelas Perez, Jose; Hambley, Bryan 03-01-2021 -12-31-2026 Biomedical Advanced Research and Development Authority A Prospective, Multicenter, Randomized, Open-Label Phase 2, Parallel, Dose Ranging Multidose Study of Thrombosomes® vs Liquid Stored Platelets (LSP) in Bleeding Thrombocytopenic Patients Role:Collaborator 0.00 Hold Level:Federal


Peer Reviewed Publications

Bryan Hambley, Kelly Norsworthy, Jagar Jasem, Jacquelyn Zimmerman et al. (2019. ) Fibrinogen consumption and use of heparin are risk factors for delayed bleeding during acute promyelocytic leukemia induction .Leukemia Research, , More Information

Alex Ambinder, Bryan Hambley, Satish Shanbhag, and Sam Merrill (2019. ) Ibrutinib-associated hemophagocytic lymphohistiocytosis: A case series from Johns Hopkins .American Journal of Hematology, , More Information

Bryan Hambley, Paolo Caimi, and Basem William (2016. ) Bortezomib for the treatment of mantle cell lymphoma: an update .Therapeutic Advances in Hematology, , More Information

Eric Gehrie et al. (2019. ) One-unit compared to two-unit platelet transfusions for adult oncology outpatients .Vox Sanguinis, , More Information

Book Chapter

Bryan Hambley and Amy DeZern (2020 ) Treatment Algorithms for Higher-Risk Disease Diagnosis and Management of Myelodysplastic Syndromes .

Contact Information

The Vontz Center for Molecular Studies
3125 Eden Ave
Cincinnati  Ohio, 45219